Cellebrite DI (CLBT) Common Equity (2020 - 2025)

Cellebrite DI's Common Equity history runs 6 years deep, the most recent figure standing at $484.3 million for Q4 2025.

• On a quarterly basis, Common Equity rose 44.13% year-over-year to $484.3 million in Q4 2025; TTM through Dec 2025 was $484.3 million, a 44.13% increase from a year earlier, with the FY2025 full-year figure at $484.3 million, up 44.13% from the prior year.
• Common Equity grew to $484.3 million in Q4 2025 per CLBT's latest filing, from $447.7 million in the prior quarter.
• Across five years, Common Equity topped out at $484.3 million in Q4 2025 and bottomed at -$130.0 million in Q3 2021.
• The 5-year median for Common Equity is $38.6 million (2023), against an average of $130.1 million.
• Across the five-year window, Common Equity plunged 328.75% in 2024 and soared 1461.09% in 2025, its largest moves.
• Year by year, Common Equity stood at -$73.3 million in 2021, then jumped by 200.71% to $73.9 million in 2022, then tumbled by 53.68% to $34.2 million in 2023, then soared by 882.17% to $336.0 million in 2024, then soared by 44.13% to $484.3 million in 2025.
• Per Business Quant, the three latest CLBT Common Equity figures stand at $484.3 million (Q4 2025), $447.7 million (Q3 2025), and $408.4 million (Q2 2025).